Moderna Therapeutics to Present at 2016 J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™, announced today that Stéphane Bancel, Chief Executive Officer, will present a company overview and pipeline update at the 34^th Annual J.P. Morgan Healthcare Conference.

Mr. Bancel will focus on Moderna's progress to accelerate drug discovery and expand the company's clinical development pipeline across an expansive number of drug modalities and therapeutic areas. Moderna's proprietary approach utilizes mRNA to instruct native cellular machinery to make proteins in vivo, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.

Moderna's pipeline includes programs being pursued by the company's four ventures:

Valera - Infectious Diseases

Elpidera - Rare Diseases

Onkaido - Immuno-Oncology

Caperna – Personalized Oncology Vaccines

as well as programs being advanced with its partners: Astra-Zeneca AZN, Alexion ALXN, Merck MRK and DARPA.

Mr. Bancel's presentation will take place on Monday, January 11, 2016 at 2:00 p.m. PT in Elizabethan C/D at the Westin St. Francis Hotel in San Francisco.

For more information on Moderna Therapeutics, including how mRNA works, partnership opportunities and job opportunities, visit www.modernatx.com.

About Moderna Therapeutics

Moderna is pioneering messenger RNA Therapeutics™, an entirely new in vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of disease conditions. The company currently plans to develop and commercialize its innovative mRNA drugs through a combination of strategic relationships as well as newly formed ventures, including Onkaido Therapeutics LLC, focused on oncology drug development, Valera LLC, focused on infectious diseases, Elpidera LLC, focused on rare diseases, and Caperna LLC, focused on personalized cancer vaccines. Founded by Flagship VentureLabs^®, Cambridge-based Moderna is privately held and currently has strategic agreements with AstraZeneca, Alexion Pharmaceuticals and Merck. www.modernatx.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160104005034/en/